TOP-509-YI Validation and improvement of the IMbrave050 criteria for high-risk of HCC-recurrence as an indication to adjuvant treatment: results from a 4-year retrospective competitive-risk study

Autor: Serenari, Matteo, Cescon, Matteo, Bonatti, Chiara, Stefanini, Bernardo, Penazza, Sofia, Prosperi, Edoardo, Dajti, Elton, Tovoli, Francesco, Ravaioli, Matteo, Piscaglia, Fabio, Ravaioli, Federico
Zdroj: In Journal of Hepatology June 2024 80 Supplement 1:S390-S390
Databáze: ScienceDirect
Externí odkaz: